RichardMTroschMD

PubMed

• The Clinician's Tardive Inventory (CTI): A New Clinical Tool for Documenting and Rating Tardive Dyskinesia.
  Shillington, A., LaChappelle, B., Trosch, R., Comella, C., Caroff, S., Ondo, W., Hauser, R., Correll, C., Friedman, J.> ;The Journal of Clinical Psychiatry. 2024 Jan 24
• 2 citations
  AbobotulinumtoxinA using 2-mL dilution (500 U/2-mL) maintains durable improvement across multiple treatment cycles
  Khashayar Dashtipour, Stefan Wietek, Bruce Rubin, Pascal Maisonobe, Laxman B. Bahroo, Richard Trosch> ;Journal of Clinical Movement Disorders. 2020 Aug 31
• 31 citations
  Safety and Efficacy of RimabotulinumtoxinB for Treatment of Sialorrhea in Adults: A Randomized Clinical Trial.
  Stuart Isaacson, William G. Ondo, Carlayne E. Jackson, Richard Trosch, Eric Molho, Fernando Pagan, Mark F. Lew, Khashayar Dashtipour, Thomas Clinch, Alberto J. Espay> ;JAMA Neurology. 2020 Apr 1
• 6 citations
  Impact of abobotulinumtoxinA on the clinical features of cervical dystonia in routine practice.
  Richard Trosch, Vijay P. Misra, Pascal Maisonobe, Savary Om> ;Clinical Parkinsonism & Related Disorders. 2020 Jan 1
• 12 citations
  Deep Brain Stimulation in Isolated Dystonia With a GNAL Mutation
  Harini Sarva, Richard Trosch, Zelma H. T. Kiss, Sarah Furtado, Marta San Luciano, Amanda Glickman, Deborah Raymond, Laurie J. Ozelius, Susan B. Bressman, Rachel Saunde...> ;Movement Disorders. 2019 Feb 1
• 5 citations
  Spectrum of practice in the routine management of cervical dystonia with abobotulinumtoxinA: findings from three prospective open-label observational studies.
  Vijay P. Misra, Richard Trosch, Pascal Maisonobe, Savary Om> ;Journal of Clinical Movement Disorders. 2018 Jul 9
• 19 citations
  Minimal clinically important change in the Toronto Western Spasmodic Torticollis Rating Scale.
  Alberto J. Espay, Richard Trosch, Gustavo Suarez, Jonathan Johnson, Dominic Marchese, Cynthia L. Comella> ;Parkinsonism & Related Disorders. 2018 Jul 1
• 25 citations
  Multicenter observational study of abobotulinumtoxinA neurotoxin in cervical dystonia: The ANCHOR-CD registry
  Richard Trosch, Alberto J. Espay, Daniel D. Truong, Ramon Gil, Carlos Singer, Peter A. LeWitt, Mark F. Lew, Michele Tagliati, Charles H. Adler, Jack J. Chen, Dominic M...> ;Journal of the Neurological Sciences. 2017 May 15
• Poster 296 AbobotulinumtoxinA Injection Patterns in Patients with Cervical Dystonia from the ANCHOR-CD Registry Study.
  Cynthia L. Comella, George C. Camba, Daniel D. Truong, Alberto J. Espay, Daniel Snyder, Dominic Marchese, Richard Trosch> ;PM & R. 2016 Sep 1
• Poster 182 Baseline Characteristics of Cervical Dystonia Subjects in Observational Routine-Practice Studies are Different to Those from Randomized Controlled Trials.
  Vijay P. Misra, Richard Trosch, Pascal Maisonobe, Savary Om> ;PM & R. 2016 Sep 1
• Poster 498 Geographic Differences in the Characteristics of Cervical Dystonia Patients
  Richard Trosch, Vijay P. Misra, Savary Om, Pascal Maisonobe> ;PM & R. 2016 Sep 1
• 3 citations
  Physicians' experience with RYTARY (carbidopa and levodopa) extended-release capsules in patients who have Parkinson disease
  Dee E. Silver, Richard Trosch> ;Neurology. 2016 Apr 5
• 4 citations
  A Retrospective, Single-Center Comparative Cost Analysis of OnabotulinumtoxinA and AbobotulinumtoxinA for Cervical Dystonia Treatment
  Richard Trosch, Alicia C. Shillington, Marci L English, Dominic Marchese> ;Journal of Managed Care & Specialty Pharmacy. 2015 Oct 19
• 212 citations
  Mutations in GNAL cause primary torsion dystonia.
  Tania Fuchs, Rachel Saunders-Pullman, Ikuo Masuho, Marta San Luciano, Deborah Raymond, Stewart A. Factor, Anthony E. Lang, Tsao-Wei Liang, Richard Trosch, Sierra R. Wh...> ;Nature Genetics. 2013 Jan 1
• 32 citations
  Comparison of dysphagia before and after deep brain stimulation in Parkinson's disease.
  Alice K. Silbergleit, Peter A. LeWitt, Fred Junn, Lonni Schultz, Denise Collins, Tausha Beardsley, Meghan Hubert, Richard Trosch, Jason M. Schwalb> ;Movement Disorders. 2012 Dec 1
• 19 citations
  Intermittent Subcutaneous Apomorphine Therapy for 'Off' Episodes in Parkinson's Disease : A 6-Month Open-Label Study
  Richard M Trosch, Dee E. Silver, Peter B Bottini> ;CNS Drugs. 2008 Jan 1
• 6 citations
  Botulinum toxin type B (Myobloc®) in subjects with hemifacial spasm: Results from an open-label, dose-escalation safety study†
  Richard M. Trosch, Charles H. Adler, Eric J. Pappert> ;Movement Disorders. 2007 Jul 15
• 60 citations
  Subcutaneous apomorphine in patients with advanced Parkinson's disease: A dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation ...
  Rajesh Pahwa, W. C. Koller, Richard Trosch, James H. Sherry> ;Journal of the Neurological Sciences. 2007 Jul 15
• 13 citations
  Neuroleptic-Induced Movement Disorders: Deconstructing Extrapyramidal Symptoms
  Richard M. Trosch> ;Journal of the American Geriatrics Society. 2004 Dec 1
• Modeling effective treatment of psychoses in the elderly: a focus on avoiding movement disorders.
  Richard M. Trosch> ;Journal of the American Geriatrics Society. 2004 Dec 1
• Managing psychosis in long-term care: treating the whole patient.
  Pierre N. Tariot, Richard M. Trosch, John W. Newcomer> ;Journal of the American Medical Directors Association. 2003 Jul 1
• 1 citations
  Current and emerging treatments for cervical dystonia.
  Stewart A. Factor, Mark F. Lew, Richard Trosch> ;CNS Spectrums. 2000 Jun 1
• 29 citations
  Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia.
  M F Brin, M F Lew, C H Adler, C L Comella, S A Factor, J Jankovic, C O'Brien, J J Murray, J D Wallace, A Willmer-Hulme, M Koller> ;Neurology. 1999 Oct 22
• 77 citations
  Clozapine use in Parkinson's disease: A retrospective analysis of a large multicentered clinical experience
  Richard M. Trosch, Joseph H. Friedman, Meg C. Lannon, Rajesh Pahwa, Diane Smith, Lauren Seeberger, Christopher F. O'Brien, Peter A. LeWitt, William C. Koller> ;Movement Disorders. 1998 May 1
• 14 citations
  Botulinum toxin in the treatment of tardive dystonia.
  Anjan Chatterjee, Mark Forrest Gordon, Nir Giladi, Richard Trosch> ;Journal of Clinical Psychopharmacology. 1997 Dec 1
• Join now to see all

Journal Articles

• Sodium nitoprusside and hypertension in neurologic illness.  
  Trosch RM, Raps EC, Fink ME, NEJM
• The effects of aging on cerebral blood flow in patients with migraine equivalents.  
  Robertson WM, Ramadan NM, Levine SR, Schultz LR, Trosch RM, Welch KMA, Neurology
• Localization of emotional facial paresis.  
  Trosch RM, Waxman SG, Brass LM, Neurology
• Botulinum A toxin injections for the treatment of hand tremors.  
  Trosch RM, Pulman S, Ann Neurology
• Botulinum A toxin treatment of hemimasticatory spasm in Parry Romberg syndrome.  
  Trosch Rm, Rontal M, Movement Disorders
• Clozapine treatment of dystonia in Parkinson’s disease.  
  Trosch Rm, Friedman JH, LeWitt PA, Movement Disorders
• Clozapine use in Parkinson’s disease.  
  Trosch RM, Neurology
• Unexpected outcomes with tolcapone in Parkinson’s disease.  
  Trosch RM, LeWitt PA, Movement Disorders
• Westphal variant of Huntington’s disease masquerading as MSA.  
  Trosch RM, LeWitt PA, Movement Disorders
• An open-label trial of tolcapone in Parkinson’s disease.  
  Davis TL, Charles PD, Saint-Hilaire MH, Trosch RM, LeWitt PA, Kurth MC, Pedder S, Dorflinger E, Movement Disorders
• Botulinium toxin type B decreases pain in patients with cervical dystonia.  
  Trosch RM, Pain Medicine
• GNAL is a new causative gene for Primary Dystonia.  
  Fuchs T1, Saunders-Pullman R2,3, Masuho I4, San Luciano M5, Raymond D2, Factor S6, Lang AE7, Liang TW8, Trosch RM9, White S1, Ainehsazan E1, Herve D10, Sharma N11, Ehr..., Nature Genetics
• Safety and efficacy of pramipexole in early Parkinson’s disease: A randomized dose-ranging study.  
  The Parkinson Study Group, JAMA
• Pramipexole in Levodopa-treated Parkinson’s disease patients of africian, asian, and Hispanic heritage.  
  Parkinson Study Group, Clin Neuropharmacol
• Join now to see all